Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome

<div>Effect of tocilizumab on inflammatory markers. IL-6, interleukin-6; CRP, <i>C</i>-reactive protein.</div>

Case Reports in Nephrology

fig1

Figure 1

Figure 1: Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome 

Figure 1 | Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome 